Leaflet: information for the user
Doxilamina Esteve 12.5 mg film-coated tablets
Hydrogen succinate of doxilamina
Read this leaflet carefully before you start taking this medicine, because it contains important information for you
Follow exactly the administration instructions of the medicine contained in this leaflet or those indicated by your doctor or pharmacist.
1.What is Doxilamina Esteve and for what it is used
2.What you need to know beforestarting totake Doxilamina Esteve
3.How to take Doxilamina Esteve
4.Possible adverse effects
5Storage of Doxilamina Esteve
6.Contents of the package and additional information
Doxilamina Esteve is a medication that contains the active ingredient doxilamina hydrogenosuccinate. Doxilamina belongs to a group of medications called antihistamines, which have sedative properties.
It is indicated for the short-term symptomatic treatment of occasional insomnia in individuals over 18 years old.
Consult a doctor if symptoms worsen or do not improve after 7 days.
Do not take Doxilamina Esteve
Warnings and precautions
Consult your doctor or pharmacist before starting to take Doxilamina Esteve.
You should consult a doctor before taking this medication if you have:
Do not administer Doxilamina Esteve for periods of more than 7 days, unless your doctor recommends it.
Children and adolescents
Do not recommend the administration of Doxilamina Esteve to children under 18 years old.
Taking Doxilamina Esteve with other medications
Inform your doctor or pharmacist that you are taking, have taken recently or may need to take any other medication.
Do not take Doxilamina Esteve with the following medications:
You should avoid taking Doxilamina Esteve with the following medications, as they may potentiate its action or adverse effects:
Interference with diagnostic tests
Doxilamina may interfere with skin allergy tests that use allergens. It is recommended to discontinue Doxilamina Esteve treatment at least three days before starting these tests.
Taking Doxilamina Esteve with food, drink and alcohol
Do not consume alcoholic beverages during Doxilamina Esteve treatment.
See section 3. How to take Doxilamina Esteve
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
There are no adequate data on the use of doxilamina in pregnant women, so you should avoid taking Doxilamina Esteve during pregnancy.
Due to the risks associated with administering antihistamines to young children, women who are breastfeeding should not take Doxilamina Esteve.
There are no data on the possible effects of Doxilamina Esteve on human fertility.
Driving and operating machinery
The influence of Doxilamina Esteve on the ability to drive and operate machinery is important, as it causes drowsiness. Do not drive or operate hazardous machinery while taking this medication, at least during the first few days of treatment until you know how it affects you.
Doxilamina Esteve contains Red 33 Lake.
This medication may cause allergic reactions because it contains Red 33 Lake. It may cause asthma, especially in patients allergic to aspirin.
Doxilamina Esteve contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the medication administration instructions contained in this leaflet or those indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist.
Adults (18 years and older)
The recommended dose is 1 to 2 tablets (12.5 mg to 25 mg) per day, taken 30 minutes before bedtime.
If daytime somnolence occurs, it is recommended to reduce the dose to 1 tablet (12.5 mg) or take it earlier to ensure at least 8 hours pass before waking up.
Do not take more than 2 tablets (25 mg) per day.
Use in the elderly
People over 65 years are more prone to other pathologies that may recommend a dose reduction. The initial recommended dose is 12.5 mg (1 tablet), taken 30 minutes before bedtime. The dose can be increased to 25 mg (2 tablets) if the initial dose does not sufficiently alleviate insomnia. In case of appearance of undesirable side effects, the dose will be 1 tablet (12.5 mg) per day. For this reason, pay attention to the effect caused by the treatment (see section 4).
Use in patients with liver or kidney disease
In patients with renal or hepatic insufficiency, it is recommended to reduce the dose to a maximum daily intake of 12.5 mg.
Use in children and adolescents
Doxilamina Esteve is not recommended for use in minors under 18 years, so the medication should not be used in this population.
Route and method of administration
Oral route.
The tablets should be taken 30 minutes before bedtime with a sufficient amount of liquid (preferably water).
Doxilamina Esteve can be taken before or after meals.
Duration of treatment
The duration of treatment should be as short as possible. In general, the duration of treatment can range from a few days to a week.
It should not be administered for a period exceeding 7 days, unless the doctor advises taking it for a longer period.
If you take more Doxilamina Esteve than you should
If you take more Doxilamina Esteve than you should, consult your doctor or pharmacist immediately.
The symptoms of an overdose are: somnolence, depression or stimulation of the central nervous system, anticholinergic effects (dilated pupils, fever, dry mouth, decreased intestinal tone), redness, increased or altered heart rate, increased blood pressure, nausea, vomiting, agitation, altered gait, dizziness, irritability, sedation, confusion, and hallucinations.
Severe intoxication can cause delirium, psychosis, decreased blood pressure, seizures, decreased respiration, loss of consciousness, and coma, and may pose a risk to life.
A severe complication can be rhabdomyolysis (muscle injury), followed by renal failure.
There is no specific antidote for antihistamine overdose, so treatment is symptomatic and supportive. Your doctor will evaluate the need to induce vomiting, perform a gastric lavage, or prescribe medications to increase blood pressure if necessary.
In case of overdose or accidental ingestion, consult the Toxicological Information Service. Phone 91.562.04.20.
If you forget to take Doxilamina Esteve
Do not take a double dose to compensate for the missed doses.
Take your dose at the usual time the next day.
If you interrupt treatment with Doxilamina Esteve
If you have any other doubts about the use of thismedication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The side effects of doxilamine are generally mild and transient, being more frequent in the first days of treatment.
Very common side effects (may affect more than 1 in 10 people): drowsiness.
Common side effects (may affect up to 1 in 10 people): symptoms such as dry mouth, constipation, blurred vision, urinary retention, increased bronchial secretion, vertigo, dizziness, headache, upper abdominal pain, fatigue, insomnia, and nervousness.
Rare side effects (may affect up to 1 in 100 people): asthenia (fatigue), peripheral edema (inflammation of arms and legs), nausea, vomiting, diarrhea, skin rash, tinnitus (ringing in the ears), orthostatic hypotension (decrease in blood pressure due to changes in posture), diplopia (double vision), dyspepsia (stomach disorders), feeling of relaxation, nightmares, and dyspnea (breathing difficulties).
Rare side effects (may affect up to 1 in 1,000 people): agitation (especially in the elderly), tremor, convulsions, or blood disorders such as hemolytic anemia, thrombocytopenia, leucopenia, or agranulocytosis (decrease in certain blood cells).
Side effects of unknown frequency (cannot be estimated from available data): general malaise.
Other side effects that have occurred with the use of antihistamines in general, although not observed with doxilamine, are the following:arrhythmia (alteration of heart frequency), palpitations, gastroesophageal reflux, abnormal liver function (jaundice), prolonged QT interval on the electrocardiogram (a cardiac alteration), decreased appetite, increased appetite, myalgia (muscle pain), abnormal coordination, extrapyramidal disorder (movement disorders), paresthesia (abnormal sensations), impairment of psychomotor activities (sensory-motor coordination), depression, decreased bronchial secretion, alopecia (hair loss), allergic dermatitis, hyperhidrosis (excessive sweating), photosensitivity reaction, or hypotension (low blood pressure).
The frequency and magnitude of side effects may be reduced by decreasing the daily dose.
People over 65 years old have a higher risk of experiencing adverse reactions, as they may have other underlying diseases or be taking other medications simultaneously. These individuals also have a higher risk of experiencing a fall.
If you experience side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this prospectus.
Adverse Effect Notification
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe box or blister packafter CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medications. By doing so, you will help protect the environment..
Composition of Doxilamina Esteve
Core excipients:
Calcium dihydrogen phosphate (E-341)
Microcrystalline cellulose (E-460)
Sodium carboxymethyl starch (type A) from potato
Anhydrous colloidal silica (E-551)
Magnesium stearate (E-572)
Coating excipients:
Microcrystalline cellulose (E-460)
Macrogol-40 stearate type I (E-431)
Propylene glycol (E-1520)
Hydroxypropyl methylcellulose (E-464)
Titanium dioxide (E-171)
Red C (E-124)
Macrogol 400
Macrogol 6000
Appearance of the product and content of the container
Doxilamina Esteve is presented in the form of coated tablets with a pink elongated film, in a container containing 7 or 14 tablets.
Only some container sizes may be commercially marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Esteve Pharmaceuticals, S.A.
Passeig de la Zona Franca, 109
08038 Barcelona
Responsible for manufacturing
TOWA Pharmaceutical Europe, S.L.
c/ de Sant Martí, 75-97
08107 Martorelles (Barcelona) Spain
This medicine is authorized in the member states of the European Economic Area with the following names;
Finland: Dormix
Norway: Zonat
Sweden: Zovin
Revision date of this leaflet: December 2020.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.